AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces risks from patent expirations and a leveraged balance sheet. Johnson & Johnson, with a more diversified product base and a AAA credit rating, offers a more stable dividend backed by strong free cash flow, making it a safer choice for retirees relying on income. Investors with longer horizons might prefer AbbVie for growth, while retirees should favor Johnson & Johnson for dividend reliability.
As of Sep 25, 2026 22:11 WIB, AbbVie trades at USD 264.19, close to its 52-week high of USD 265.97, with a dividend yield of 2.61%. Johnson & Johnson is priced slightly higher at USD 270.66, near its 52-week high of USD 278.43, offering a dividend yield of 1.98%. On Pluang, AbbVie sees heavier selling activity at 95% compared to Johnson & Johnson's 85%, reflecting differing investor sentiment on these dividend stocks.
PepsiCo, AbbVie, and Coca-Cola are highlighted as top dividend stocks to buy before the third quarter ends due to their recession resilience, strong dividend histories, and positive 2026 outlooks. PepsiCo offers the highest yield at 4.31% with steady...
The European Commission has approved RINVOQ (upadacitinib) for treating active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged two years and older who have not responded well or are intolerant to other treatments. This approval is...
AbbVie and Iambic have entered a multi-year collaboration to accelerate the discovery of small molecule drugs using Iambic's AI-driven platform. This partnership aims to improve the efficiency and success rate of identifying new drug candidates in im...
